Meda Expands Axorid Collaboration
News Dec 31, 2009
Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.
Axorid consists of the well-known and broadly used substances; ketoprofen, a NSAID (Non Sterodial Anti-Inflammatory Drug) for the treatment of rheumatic disorders, and omeprazole, an acid reducing proton pump inhibitor (PPI). Axorid can prevent gastrointestinal side effects from use of NSAIDs. Axorid’s once-daily administration can also increase patient compliance.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019